Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Business has been booming for the company, a multispecialty telehealth platform, with rapid growth in its weight loss offering, including compounded GLP-1 injection products. Hims & Hers expects ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced the resolution of the shortage of GLP-1 (semaglutide ...

Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Hims & Hers Health stock dropped 25% after the ... and retain weight loss subscribers in the coming absence of popular GLP-1 compounds.

That means Hims & Hers Health, which markets compounded versions of the two treatments, can no longer manufacture exact copies of the drugs as they did during the shortage. It also means the gravy ...

The U.S. District Court for the Northern District of Texas just ruled in a lawsuit related to GLP-1 weight loss drugs, and the ruling has negative implications for Hims & Hers' business. Where to ...

The guidance for FY 2025 includes revenue in the range of $2.3 billion to $2.4 billion vs the Street's estimate of $2.1 billion. Let's dive deep into this guidance. Hims & Hers projects 2025 GLP-1 ...